Testimony
Our work in Testimony
-
Testimony on Texas v. U.S.: The Republican Lawsuit and its Impacts on Americans with Pre- Existing Conditions
Christen Linke Young delivered testimony to the House Energy & Commerce Subcommittee on Health on February 6, 2019.
Categorized in -
Economic Aspects of the Opioid Crisis
Sir Angus Deaton testified on the decline in life expectancy in the United States and the role opioids have played in this startling trend.
-
Comments on CMS’s proposed rule for implementation of MACRA provisions
Paul Ginsburg and his colleagues suggest three ways in which CMS can further achieve its stated goal to “expand the opportunities for participation in APMs” by better supporting providers’ transition under MACRA.
Categorized in -
Fostering Competition in Consolidated Markets
Paul Ginsburg testified before the California Senate Committee on Health, focusing on implications and complexities of provider competition.
Categorized in -
Examining Consolidation in the Health Insurance Industry and its Impact on Consumers
Paul Ginsburg testified on capital hill about the proposed mergers within the insurance industry, and the impact of those mergers on consumers. In his remarks, Ginsburg noted that health insurance mega-mergers such as those sought by Aetna and Anthem are extremely complex, difficult to analyze and could cost consumers. Explaining why the health insurance market is […]
Categorized in -
How Can We Make Health Care More Affordable?
Neeraj Sood testified before the California State Senate Committee on Health.
-
Examining Health Care Competition: Limited Networks
Paul Ginsburg presented about insurance and provider networks during an FTC-DOJ workshop.
Categorized in -
Making Health Care Affordable: What’s Driving Costs?
Geoffrey Joyce provided expert testimony to the California Senate Health Committee about the role of the biomedical industry in healthcare cost trends.